Opioid impact fee bill passes Delaware Senate
DOVER, Del. – The first state has moved a step closer to holding pharmaceutical companies more accountable when it comes to the opioid crisis.
On Tuesday, the Senate passed SB 34, which would force drug makers to pay for additional research and treatment options.
It would require manufacturers pay a 4-cent fee for a single 10-milligram pill for the generic opioid oxycodone and a 15-cent fee for the brand-name equivalent.
They estimate that this increase would generate more than $8 million in the next 3 years.
Representative Steve Smyk says that he believes the bill will pass the house. Representative Smyk says, “There is not a legislator, there’s not a house member that hasn’t felt this impact on their communities, it’s devastating. We’ve lost friends and family members and people who were iconic in the communities who you thought would never be touched before.”
If it were to become a law, the money collected from the fee would be directed to a special fund to help those who are uninsured or underinsured and enroll them in treatment programs.